Your browser doesn't support javascript.
loading
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study.
Pant, Shubham; Schuler, Martin; Iyer, Gopa; Witt, Olaf; Doi, Toshihiko; Qin, Shukui; Tabernero, Josep; Reardon, David A; Massard, Christophe; Minchom, Anna; Lugowska, Iwona; Carranza, Omar; Arnold, Dirk; Gutierrez, Martin; Winter, Helen; Stuyckens, Kim; Crow, Lauren; Najmi, Saltanat; Hammond, Constance; Thomas, Shibu; Santiago-Walker, Ademi; Triantos, Spyros; Sweiti, Hussein; Loriot, Yohann.
Affiliation
  • Pant S; Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: spant@mdanderson.org.
  • Schuler M; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
  • Iyer G; Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.
  • Witt O; Hopp Children's Cancer Center (KiTZ), Heidelberg University Hospital, German Cancer Research Center and National Center for Tumor Diseases (NCT), Heidelberg, Germany.
  • Doi T; National Cancer Center Hospital East, Kashiwa, Japan.
  • Qin S; Jinling Hospital, Nanjing University of Chinese Medicine, Nanjing, China.
  • Tabernero J; Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), IOB-Quiron, Barcelona, Spain.
  • Reardon DA; Center for Neuro-Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
  • Massard C; Le Kremlin Bicêtre-France INSERM U1030, Molecular Radiotherapy, Gustave Roussy, Université Paris-Saclay, Paris, France.
  • Minchom A; The Royal Marsden NHS Foundation Trust, Sutton, UK.
  • Lugowska I; Department of Soft Tissue/Bone Sarcoma and Melanoma, Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie-Panstwowy Instytut Badawczy, Warsaw, Poland.
  • Carranza O; Hospital Privado de Comunidad de Mar del Plata, Mar del Plata, Argentina.
  • Arnold D; Department of Oncology, AK Altona, Asklepios Tumourzentrum Hamburg, Hamburg, Germany.
  • Gutierrez M; John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA.
  • Winter H; Bristol Haematology and Oncology Centre, Bristol, UK.
  • Stuyckens K; Janssen Research & Development, Beerse, Belgium.
  • Crow L; Janssen Research & Development, Spring House, PA, USA.
  • Najmi S; Janssen Research & Development, Spring House, PA, USA.
  • Hammond C; Janssen Research & Development, Spring House, PA, USA.
  • Thomas S; Janssen Research & Development, Spring House, PA, USA.
  • Santiago-Walker A; Janssen Research & Development, Spring House, PA, USA.
  • Triantos S; Janssen Research & Development, Spring House, PA, USA.
  • Sweiti H; Janssen Research & Development, Spring House, PA, USA.
  • Loriot Y; Department of Cancer Medicine, INSERM U981, Gustave Roussy, Université Paris-Saclay, Villejuif, France. Electronic address: Yohann.LORIOT@gustaveroussy.fr.
Lancet Oncol ; 24(8): 925-935, 2023 08.
Article in En | MEDLINE | ID: mdl-37541273
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Urinary Bladder Neoplasms / Carcinoma, Transitional Cell Limits: Adolescent / Female / Humans / Male Language: En Journal: Lancet Oncol Journal subject: NEOPLASIAS Year: 2023 Document type: Article Country of publication: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Urinary Bladder Neoplasms / Carcinoma, Transitional Cell Limits: Adolescent / Female / Humans / Male Language: En Journal: Lancet Oncol Journal subject: NEOPLASIAS Year: 2023 Document type: Article Country of publication: United kingdom